Physician profile
Theodore Conte
NPI 1053366724
$5,218.72
in general payments reported to CMS, 2019-2025
39 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $770 · 2021: $818 · 2022: $1,048 · 2023: $583 · 2024: $719 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.56 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $432.44 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $431.93 | 2019-2022 | |
| Lilly USA, LLC | $427.78 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Neurocrine Biosciences, INC. | $342.67 | 2020-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $319.56 | 2019-2021 | |
| Kyowa Kirin, INC. | $288.29 | 2020-2025 | Nourianz |
| Novartis Pharmaceuticals Corporation | $234.07 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $181.25 | 2021-2024 | |
| Eli Lilly and Company | $175.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $145.94 | 2024-2025 | Rexulti |
| Lundbeck LLC | $116.93 | 2021-2025 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $113.18 | 2022-2024 | Apokyn, Apokyn, Xadago |
| Amneal Pharmaceuticals LLC | $100.10 | 2019-2025 | Crexont |
| Adamas Pharmaceuticals, INC. | $92.30 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Conte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.